Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBP 711

Next Previous
Drug Profile

BBP 711

Alternative Names: BBP-711; BBP-711 programme - Orfan Biotech; ORF-229

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orfan Biotech
  • Class Small molecules; Triazoles; Urologics
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria type 1
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Kidney disorders; Primary hyperoxaluria type 1

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Kidney-disorders(In volunteers) in USA (PO, Suspension)
  • 28 May 2024 No recent reports of development identified for phase-I development in Primary hyperoxaluria type 1(In volunteers) in USA (PO, Suspension)
  • 31 Dec 2022 Phase-II/III clinical trials in Primary hyperoxaluria type 1 in USA (PO) prior to December 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top